Literature DB >> 25065334

Temporal trends in all-cause mortality of smokers versus non-smokers hospitalized with ST-segment elevation myocardial infarction.

Yaron Arbel1, Shlomi Matetzky2, Natalie Gavrielov-Yusim2, Meital Shlezinger2, Gad Keren3, Arie Roth3, Eran Kopel2, Ariel Finkelstein3, Shmuel Banai3, Robert Klempfner2, Ilan Goldenberg2.   

Abstract

BACKGROUND/
OBJECTIVES: Over the past decade, the development of novel management strategies has resulted in improved outcomes among patients hospitalized with ST-segment myocardial infarction (STEMI). The aim of the present study was to compare temporal trends in the mortality of smokers versus non-smokers admitted with STEMI in a real world setting between 2000 and 2010.
METHODS: We evaluated time-dependent changes in the clinical characteristics, management strategies, and one year all-cause mortality of STEMI patients who were enrolled in the biannual Acute Coronary Syndrome Israeli Survey (ACSIS) between 2000 and 2010, categorized as smokers (n=2399) and non-smokers (n=3069). We divided the survey periods into early (2000-2004) and late (2006-2010). The primary endpoint of the study was the occurrence of one-year all-cause mortality.
RESULTS: A total of 4564 STEMI patients were enrolled in the study. Compared with non-smokers, smokers were significantly younger and displayed a significantly lower rate of all-cause mortality at 30 days and 1-year. Both smokers and non-smokers who were enrolled in the late survey period received more evidence-based therapies (primary PCI and guideline-based medications) (p<0.001 for all). There was a significant reduction in the risk of 1-year all-cause mortality only among non-smokers (HR=0.664 CI 95% 0.52-0.85, p=0.0009), whereas smokers who were enrolled in more recent survey periods did not display a significant risk reduction (HR=1.08 CI 95% 0.77-1.51, p=0.67).
CONCLUSION: Survival following STEMI among smokers has not improved over the past decade despite corresponding changes in management strategies. Future trials should focus on reducing the risk in smokers.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Mortality; Primary PCI; STEMI; Smoker's paradox; Smoking; Trends

Mesh:

Year:  2014        PMID: 25065334     DOI: 10.1016/j.ijcard.2014.07.010

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Smoking and cardiac rehabilitation participation: Associations with referral, attendance and adherence.

Authors:  Diann E Gaalema; Alexander Y Cutler; Stephen T Higgins; Philip A Ades
Journal:  Prev Med       Date:  2015-04-18       Impact factor: 4.018

2.  Video-Only Cardiopulmonary Resuscitation Education for High-Risk Families Before Hospital Discharge: A Multicenter Pragmatic Trial.

Authors:  Audrey L Blewer; Mary E Putt; Lance B Becker; Barbara J Riegel; Jiaqi Li; Marion Leary; Judy A Shea; James N Kirkpatrick; Robert A Berg; Vinay M Nadkarni; Peter W Groeneveld; Benjamin S Abella
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-10-04

3.  Association of Smoking Cessation and Survival Among Young Adults With Myocardial Infarction in the Partners YOUNG-MI Registry.

Authors:  David W Biery; Adam N Berman; Avinainder Singh; Sanjay Divakaran; Ersilia M DeFilippis; Bradley L Collins; Ankur Gupta; Amber Fatima; Arman Qamar; Josh Klein; Jon Hainer; Michael J Blaha; Marcelo F Di Carli; Khurram Nasir; Deepak L Bhatt; Ron Blankstein
Journal:  JAMA Netw Open       Date:  2020-07-01

4.  Temporal trends in healthcare resource utilization and costs following acute myocardial infarction.

Authors:  Arthur Shiyovich; Harel Gilutz; Jonathan Eli Arbelle; Dan Greenberg; Ygal Plakht
Journal:  Isr J Health Policy Res       Date:  2020-02-12

Review 5.  Impact of Modifiable Cardiovascular Risk Factors on Mortality After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of 100 Studies.

Authors:  Pravesh Kumar Bundhun; Zi Jia Wu; Meng-Hua Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.